Palbociclib, Trastuzumab, and Endocrine Therapy in Pretreated HER2-Positive and PAM50 Luminal Advanced Breast Cancer: Randomized Phase II, SOLTI-1303 PATRICIA Trial
Combining palbociclib, trastuzumab, and ET was safe and significantly improved PFS, compared with TPC, in previously treated patients with HER2-positive, PAM50 luminal A/B advanced breast cancer.
Authors
- Xavier González (ORCID: https://orcid.org/0000-0002-5797-7037)
- Blanca Cantos (ORCID: https://orcid.org/0000-0003-2105-1213)
- Sònia Pernas (ORCID: https://orcid.org/0000-0002-1485-5080)
- Guillermo Villacampa (ORCID: https://orcid.org/0000-0003-4868-6585)
- J.M. Ferrero-Cafiero (ORCID: https://orcid.org/0000-0001-8796-8812)
- Juan de la Haba-Rodríguez (ORCID: https://orcid.org/0000-0001-5111-1702)
- Tomás Pascual (ORCID: https://orcid.org/0000-0001-8431-3183)
- Rodrigo Sánchez-Bayona (ORCID: https://orcid.org/0000-0002-5255-6620)
- Antònia Regís Perelló (ORCID: https://orcid.org/0000-0002-5273-8467)
- Antonio Mulero‐Sánchez (ORCID: https://orcid.org/0000-0003-1668-7022)
- Javier Cortés (ORCID: https://orcid.org/0000-0001-7623-1583)
- Lorea Villanueva (ORCID: https://orcid.org/0000-0003-1858-7076)
- Mafalda Oliveira (ORCID: https://orcid.org/0000-0001-9152-8799)
- Patricia Galván (ORCID: https://orcid.org/0000-0002-8153-0307)
- Mireia Mele
- José Ponce (ORCID: https://orcid.org/0000-0002-0491-901X)
- Esther Sanfeliu (ORCID: https://orcid.org/0000-0002-7974-3346)
- Eduardo Martínez de Dueñas (ORCID: https://orcid.org/0000-0003-0110-4816)
- Santiago Escrivá-de-Romaní (ORCID: https://orcid.org/0000-0001-7816-7589)
- Eva Ciruelos (ORCID: https://orcid.org/0000-0002-2796-1042)
- Patricia Villagrasa (ORCID: https://orcid.org/0000-0002-8662-3641)
- Aleix Prat (ORCID: https://orcid.org/0000-0003-2377-540X)
- Álvaro Montaño (ORCID: https://orcid.org/0000-0001-5426-291X)
- Ana López-González (ORCID: https://orcid.org/0000-0003-2399-7264)
Institutions
- Hebron University (PS)
- University of Alicante (ES)
- Breast Cancer Research Foundation (US)
- Villa Maria Hospital (UG)
- Research Institute Hospital 12 de Octubre (ES)
- Institut d'Investigació Biomédica de Bellvitge (ES)
- Instituto Oncológico Dr. Rosell (ES)
- Consorcio Hospitalario Provincial de Castellón (ES)
- Hospital Universitario 12 De Octubre (ES)
- Vall d'Hebron Institut de Recerca (ES)
- Hospital Universitario Puerta de Hierro Majadahonda (ES)
- Institut Català d'Oncologia (ES)
- Hospital Quirónsalud Barcelona (ES)
- Hospital Clínic de Barcelona (ES)
- Hospital General de Catalunya (ES)
- HM Hospitales (ES)
- Hospital Universitario Reina Sofía (ES)
- Vall d'Hebron Hospital Universitari (ES)
- Solti (ES)
- Hospital General Universitario de Alicante Doctor Balmis (ES)
- Oryzon Genomics (Spain) (ES)
- Hospital Universitari Sant Joan de Reus (ES)
- Hospital Universitario Son Espases (ES)
- Hospital Universitario Virgen del Rocío (ES)
- Spanish Ovarian Cancer Research Group (ES)
- Fundació Clínic per a la Recerca Biomèdica (ES)
- GEICAM – Spanish Breast Cancer Group (ES)
- Complejo Asistencial Universitario de Palencia (ES)
- Vall d'Hebron Institute of Oncology (ES)
- Fundació de Recerca Clínic Barcelona-Institut d’Investigacions Biomèdiques August Pi i Sunyer (ES)
- Universidad de León (ES)
- Universidad Europea de Madrid (ES)
Publication Details
- Journal
- Clinical Cancer Research
- Published
- 2025-12-03
- DOI
- https://doi.org/10.1158/1078-0432.ccr-25-2882
- Primary Topic
- Advanced Breast Cancer Therapies
- Type
- article
- Field-Weighted Citation Impact
- 0.00